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Abstract
Background: von Hippel-Lindau disease is characterized by a spectrum of hypervascular tumors, including renal cell
carcinoma, hemangioblastoma, and pheochromocytoma, which occur with VHL genotype-specific differences in
penetrance. VHL loss causes a failure to regulate the hypoxia inducible factors (HIF-1a and HIF-2a), resulting in
accumulation of both factors to high levels. Although HIF dysregulation is critical to VHL disease-associated renal
tumorigenesis, increasing evidence points toward gradations of HIF dysregulation contributing to the degree of
predisposition to renal cell carcinoma and other manifestations of the disease.
Methodology/Principal Findings: This investigation examined the ability of disease-specific VHL missense mutations to
support the assembly of the VBC complex and to promote the ubiquitylation of HIF. Our interaction analysis supported
previous observations that VHL Type 2B mutations disrupt the interaction between pVHL and Elongin C but maintain partial
regulation of HIF. We additionally demonstrated that Type 2B mutant pVHL forms a remnant VBC complex containing the
active members ROC1 and Cullin-2 which retains the ability to ubiquitylate HIF-1a.
Conclusions: Our results suggest that subtypes of VHL mutations support an intermediate level of HIF regulation via a
remnant VBC complex. These findings provide a mechanism for the graded HIF dysregulation and genetic predisposition for
cancer development in VHL disease.
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Introduction
von Hippel-Lindau (VHL) disease is an autosomal dominant
familial cancer syndrome caused by germline mutation or loss of
the VHL tumor suppressor gene that affects approximately 1 in
36,000 individuals [1]. Individuals with VHL disease develop an
array of tumors, including clear cell renal cell carcinomas
(ccRCC), cerebellar and retinal hemangioblastomas, and pheo-
chromocytomas [1]. VHL disease is divided by genotype into
subtypes which predict the spectrum of risk for development of
VHL-associated lesions [2–4]. Type 1 VHL disease predisposes to
the development of ccRCC and hemangioblastoma. All patients
with Type 2 VHL disease are at risk for pheochromocytoma. Type
2A VHL disease is further characterized by high risk for
hemangioblastoma, and Type 2B VHL disease is associated with
high risk for both hemangioblastoma and RCC. Type 2C VHL
disease individuals exclusively develop pheochromocytoma [5].
Patients homozygous for the Arg200Trp (R200W) VHL mutation,
located in the extreme C-terminal domain of the 213 amino acid
VHL protein (pVHL), develop Chuvash Polycythemia [6,7].
Biallelic inactivation of pVHL has also been reported in upwards
of 90% of individuals with sporadic ccRCC [8]. Thus, a thorough
understanding of wild-type and disease-associated mutant pVHL
activities has potential to impact a broad spectrum of affected
patients [1,9,10].
The VHL protein acts as the substrate recognition subunit of an
E3 ubiquitin ligase complex analogous in structure to the SCF
complex. The SCF and SCF-like complexes typically contain four
subunits, including a RING finger protein (ROC1/Rbx1), a cullin
protein (CUL/Cul), and two adaptor proteins linking the cullin to
the substrate binding protein [11]. In the pVHL E3 complex
(VBC), pVHL acts as the substrate binding protein and is
responsible for the specificity of the complex-target interaction
[12]. Human pVHL directly interacts with Elongin C, while
Elongin B links pVHL-Elongin C to cullin 2 (CUL2)-ROC1 [13–
15]. The VBC complex serves as a platform through which the E2
ubiquitin-conjugating enzyme, bound by CUL2-ROC1, and the
pVHL-bound substrate are brought into proper positioning for
ubiquitin transfer [11]. In the VBC complex, ROC1 functions to
recruit the E2 enzyme and also promotes internal complex
stability [12,14].
The primary targets of the VBC complex are the hypoxia
inducible factors, HIF-1a and HIF-2a. The HIF factors direct the
transcriptional response to hypoxia by activating the expression of
genes involved in angiogenesis, cell proliferation, erythropoiesis,
energy metabolism, and apoptosis [16–21].
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Loss of the pVHL tumor suppressor, as occurs with Type 1 VHL
mutations, is believed to promote renal tumorigenesis primarily
through loss of pVHL-mediated HIF regulation [22]. Corre-
spondingly, Type 2C VHL missense mutations display fully intact
regulation of HIF factors, consistent with the lack of conveyed risk
for RCC development [23]. In the case of Type 2A and Type 2B
VHL missense mutations, titrated degrees of HIF regulation
appear to correlate with the subtype-specific risk of ccRCC
[21,24]. While the differing capabilities of VHL disease-associated
mutants to regulate HIF have been explored [20,21,23–25], the
mechanism of retained HIF regulation and the link between
differing levels of HIF regulation and the clinical spectrum
observed in VHL disease is not yet fully understood. In this study,
we re-examined the effect of VHL missense mutations to disrupt
the formation of the VBC complex, and demonstrate that
characteristic Type 2B VHL mutations form a low-abundance
VBC complex which retains the ability to ubiquitylate HIF-1a.
Materials and Methods
Cell Lines
Vhl-null embryonic stem (ES) cells or VHL-deficient 786-0 RCC
cells were transfected with vectors specifying human wild-type
VHL or representative VHL mutants Y112H (Type 2A), R167Q
(Type 2B), L188V (Type 2C), or R200W (Chuvash polycythemia)
using vectors and techniques as previously described [25]. 786-0
cells expressing the VHL mutant D121G (Type 2B), generated as
previously described [26], were generously provided by Dr.
William Kim, Chapel Hill, NC. Vhl-null murine ES cells and
transfected derivatives were maintained in culture media com-
prised of Dulbecco’s Modified Eagle Medium (DMEM, various
manufacturers), supplemented with 10% ES cell-certified fetal
bovine serum (Invitrogen, Carlsbad, CA), non-essential amino
acids, L-glutamine, 2-mercaptoethanol, and leukemia inhibitory
factor, and were grown on gelatin-coated plates in the absence of
feeder cells. Renal cell carcinoma 786-0 cells were acquired from
the American Type Culture Collection (Manassas, VA). 786-0 cells
and transfected derivatives were maintained in DMEM, supple-
mented with 10% FBS, non-essential amino acids, L-glutamine,
and 2-mercaptoethanol. All cultures were maintained at 37uC in
5% CO2. For hypoxia mimetic experiments, cells in log-phase
growth were placed in media supplemented with 100 mM cobalt
chloride (Sigma, St. Louis, MO) or fresh unsupplemented media.
Immunoblot Analysis
Cells were lysed in Mammalian Protein Extraction Reagent (M-
PER; Pierce Biotechnology, Rockford, IL) supplemented with
Complete Mini Protease Inhibitor Cocktail (Roche, Basel,
Switzerland). The Bradford Quantification Method (Amresco,
Solon, OH) was used to determine protein concentration. Cell
lysates were resolved by SDS-PAGE and subsequently transferred
to Hybond ECL nitrocellulose membrane (GE Healthcare, United
Kingdom). Immediately following transfer, membranes were
stained with Ponceau S to confirm even transfer, blocked in 5%
nonfat dry milk diluted in phosphate-buffered saline containing
0.1% Tween-20 (PBS-T), and then probed with the following
primary antibodies: rabbit polyclonal anti-HA tag (Abcam,
Cambridge, MA: ab9110, 1:1000), mouse monoclonal anti-pVHL
(Abcam, ab11189, 1:2000), rabbit polyclonal anti-cullin-2 (Abcam:
ab1870, 1:1000), rabbit polyclonal anti-ROC1 (Abcam: ab2977,
1:500), goat polyclonal anti-Elongin C (Santa Cruz, Santa Cruz,
CA: sc-1559, 1:200), rabbit polyclonal anti-Elongin B (Santa Cruz:
sc-11447, 1:200), mouse monoclonal anti-Myc tag (Cell Signaling,
Danvers, MA: 9B11, 1:1000), mouse monoclonal anti-HIF-2a
(GeneTex, San Antonio, TX: GTX30123, 1:1000), and rabbit
polyclonal anti-Ku80 (GeneTex: GTX70485, 1:2000). Secondary
antibodies used were anti-mouse, anti-rabbit, and anti-goat IgG
conjugated to horseradish peroxidase (various manufacturers) and
detected with the ECL Plus Western Blotting System (GE
Healthcare) using exposure to BlueLite autoradiography film
(ISC BioExpress, Kaysville, UT) and processing via a Kodak RP
X-OMAT Processor (Rochester, NY).
Immunoprecipitation Analysis
M-PER cell lysates were subjected to immunoprecipitation (IP)
using either the Profound Mammalian HA Tag IP/Co IP Kit or the
Profound Mammalian Myc Tag IP/Co IP Kit, as per manufacturer’s
specifications (Pierce Biotechnology). For the reverse co-IP analysis,
stably-transfected 786-0 cell lines were transiently transfected with a
plasmid encoding myc-tagged cullin-2, a generous gift from Dr. Y.
Xiong, Chapel Hill, NC, using Solution V of the Amaxa Tranfection
System (Amaxa, Gaithersberg, MD). Twenty hours post-transfection,
transfected cells were incubated in media supplemented with 5 mM
MG-132 (Calbiochem, Gibbstown, NJ) proteasome inhibitor or fresh
unsupplemented media for four hours, followed by protein extraction
with M-PER and IP analysis as above.
In vitro HIF-1a Ubiquitylation Assay
An in vitro ubiquitylation assay was adapted from the protocol
developed by Cockman et al. [18]. 786-0 cell lines incubated for four
hours in 5 mM MG-132 were washed and collected in PBS. The cells
were then washed twice in Ub Extraction Buffer (20 mM Tris,
pH 7.5, 5 mM Kcl, 1.5 mM MgCl2, 1 mM DTT) and disrupted
using a dounce homogenizer. The cell lysates were centrifuged at
10,0006g for 10 minutes at 4uC. Each reaction was set up in a total
volume of 40 mL, containing 23 mL cell extract, 5 mL HIF1a-myc
substrate, and 12 mL reaction solution. The ‘‘reaction solution’’ was
composed of ATP Regenerating System (20 mM Tris, pH 7.5,
10 mM ATP (GE Healthcare)), 10 mM magnesium acetate
(Promega Corporation, Madison, WI), 300 mM creatine phosphate,
0.5 mg/mL creatine phosphokinase (MP Biomedicals, LLC, Irvine,
California), 20 mg ubiquitin, and 150 uM ubiquitin aldehyde (Biomol
International, Plymouth Meeting, PA). When reactions excluded a
specific component, nuclease-free dH2O was substituted to maintain
the total reaction volume. Reactions were incubated at 30uC for
270 minutes and then subjected to immunoblot analysis. HIF1a-myc
substrate was produced through TNTH coupled Wheat Germ
Extract Systems (Promega, Madison, WI) from a plasmid encoding
full-length functional human HIF1a-myc protein, a generous gift
from Dr. M. C. Simon, Philadelphia, PA.
Results
Type 2B mutant pVHL proteins promote incomplete
normoxic HIF-2a stabilization
We have previously shown that human VHL mutations
representative of Types 2A and 2B VHL disease impart an
intermediate degree of HIF-2a regulation in a Vhl-null murine ES
cell expression system [25]. In order to evaluate this trend in
human RCC cells, 786-0 RCC-derived cells, known to lack pVHL
expression and over-express HIF-2a, were reconstituted with
expression vectors encoding wild-type or VHL disease-specific
mutant VHL cDNA. Individual clones expressing mutant pVHL
comparable to wild-type levels were selected for subsequent
experiments. Figure 1A depicts a representative immunoblot for
the expression of wild-type as well as RCC-associated Type 2A
(Y112H) and 2B (R167Q) mutant HA-tagged pVHL in 786-0
RCC clones.
Type 2B VHL E3 Ligase Complex
PLoS ONE | www.plosone.org 2 November 2008 | Volume 3 | Issue 11 | e3801
To study the ability of RCC-associated mutant pVHL to
regulate HIF in 786-0 cells, the hypoxia mimetic cobalt chloride
(CoCl2) was used to simulate hypoxic conditions. Cells were placed
in either standard growth media or media supplemented with
100 mM CoCl2for 24 hours followed by analysis of HIF-2a
protein levels by immunoblot (Figure 1B). VHL-null vector-only
transfected cells (vector) failed to suppress HIF-2a under standard
conditions and lacked further induction under simulated hypoxic
conditions. Introduction of wild-type HA-pVHL restored nor-
moxic suppression and CoCl2 induction of HIF-2a. Type 2A VHL
mutant Y112H cells failed to completely suppress HIF-2a levels, as
expected due to the predicted disruption of the HIF interaction
domain [15]. Type 2B VHL mutant R167Q cells displayed partial
suppression of HIF-2a while retaining HIF-2a stabilization in
response to CoCl2. These observations were confirmed in multiple
independently-derived 786-0 clones (data not shown).
Type 2B mutant protein participates in a VBC complex
containing Cullin2
To determine the correspondence between the observed partial
retention of HIF-2a regulation and formation of a competent
VBC complex, we analyzed the interaction of wild-type and
disease-specific mutant HA-pVHL with known components of the
VBC complex by co-IP and reverse co-IP studies in transgenic
human 786-0 and murine ES cells. Based on prevailing models,
Type 2B mutant pVHL proteins, including R167Q, are predicted
to disrupt VBC complex formation by eliminating Elongin C
binding to pVHL [13,27–30]. We have previously observed the
inability of R167Q HA-pVHL to bind Elongin C in a transgenic
murine ES cell system [25].
VBC complex formation was assessed by co-IP analysis of
proteins interacting with HA-pVHL in Vhl-null murine ES cells
expressing wild-type pVHL (WT), mutants Y112H, R167Q,
L188V, and R200W, or no transgene (2/2). HA-pVHL pull-
down was confirmed in each IP by anti-HA immunoblot (HA,
Figure 2A). Each HA-pVHL-containing complex was then
individually tested for interaction with known members of the
VBC complex through protein-specific co-IP immunoblot
(Figure 2A). As expected based on both previous reports and the
localization of the respective mutations [20,25], the R167Q HA-
pVHL failed to substantially co-immunoprecipitate Elongin C,
whereas wild-type HA-pVHL and mutant HA-pVHL representing
Y112H, L188V, and R200W retained this interaction. Further-
more, wild-type HA-pVHL and mutant HA-pVHL representing
Y112H, L188V, and R200W demonstrated interaction with
complete VBC complex detecting the presence of murine Elongin
B, Cul2, and Rbx1. Elongin B, Cul2, and Rbx1 also clearly
associated with the R167Q HA-pVHL, suggesting that the VBC
complex is at least partially intact in cells expressing this
representative Type 2B VHL mutation.
In order to discern if the observed remnant VBC complex in
R167Q HA-pVHL-expressing murine ES cells was an artifact of
human-mouse interactions, we examined the same panel of VHL
Figure 1. VHL disease associated mutations demonstrate a
graded amount of HIF Regulation. A. Anti-HA immunoblot for
expression of HA-tagged human pVHL in transgenic 786-0 clones.
Whole-cell protein extracts were prepared from 786-0 clones deficient
for VHL expression (Vector) or modestly expressing wild-type (WT) or
missense (Y112H, R167Q) mutant HA-tagged human pVHL. B. Anti-HIF-
2a immunoblot for HIF stabilization in 786-0 clones. Whole-cell protein
extracts were prepared from VHL-deficient 786-0 cells or WT or mutant
HA-pVHL-rescued 786-0 cells incubated in the presence or absence of
the hypoxia mimetic CoCl2 for 24 hours. Ku80 immunoblot was used as
a control for equal loading.
doi:10.1371/journal.pone.0003801.g001
Figure 2. Co-immunoprecipitation of VBC complex proteins
with type 2B mutant pVHL. A. Anti-HA immunoprecipitation of HA-
pVHL and associated VBC complex members in transgenic ES cell
clones. Anti-HA IP products were probed for successful pull-down of WT
or mutant HA-pVHL and for co-IP of the indicated VBC complex
members in stably-transfected Vhl2/2 murine ES cells. B. and C. Anti-HA
immunoprecipitation of HA-pVHL from transgenic 786-0 clones. Anti-
HA IP products were probed for successful pull-down of WT or mutant
HA-pVHL by anti-pVHL (B) or anti-HA (C) immunoblot and for co-IP of
the indicated VBC complex members in stably-transfected 786-0 cells.
doi:10.1371/journal.pone.0003801.g002
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mutations for VBC complex formation in stably-transfected
human 786-0 RCC cells. A second representative Type 2B VHL
mutation D121G was included in this analysis to determine
whether the formation of a remnant complex is limited to the
specific Type 2B mutant R167Q HA-pVHL or is more broadly
relevant to Type 2B VHL disease. Again, pVHL-associated
proteins were co-immunoprecipitated, and pull-down of HA-
pVHL was confirmed for each IP by anti-VHL (Figure 2B) or anti-
HA (Figure 2C) immunoblot, followed by detection of known VBC
complex members by protein-specific co-IP immunoblot
(Figures 2B and 2C). Both R167Q and D121G mutant HA-
pVHL failed to demonstrate a strong interaction with Elongin C,
although robust association was detected for wild-type and the
other mutant HA-pVHL proteins. The remaining VBC complex
members were again associated with wild-type and all of the HA-
pVHL mutants tested, including the Type 2B mutants R167Q and
D121G. This experiment suggests that both of the Type 2B
mutant HA-pVHL proteins studied may retain at least partial
interaction with Elongin C and recruit a complex containing the
essential human VBC E3 ubiquitin ligase components CUL2 and
ROC1.
To confirm the observed interaction between R167Q HA-
pVHL and CUL2, a myc-tagged CUL2 protein was transiently
expressed in stable 786-0 cell lines expressing wild-type or RCC-
associated mutant HA-pVHL for reverse co-IP studies (Figure 3).
Cell extracts were subjected to anti-myc-agarose IP, and pull-
down of myc-CUL2 was confirmed by anti-CUL2 immunoblot.
Anti-HA co-IP immunoblot verified the results depicted in
Figure 2B–C, displaying myc-CUL2 interaction with wild-type,
Y112H, and R167Q HA-pVHL.
Type 2B mutant pVHL retains HIF-1a-ubiquitylating
activity
To determine if the remnant R167Q HA-pVHL–CUL2 complex
retained E3 ubiquitin ligase activity, wild-type and mutant HA-
pVHL were analyzed for competence to ubiquitinate HIF-1a using
a modified version of the in vitro assay developed by Cockman et al.
[18]. Exogenous HIF-1a was used as the ubiquitylation target in this
experiment as the 786-0 parental cell line lacks confounding
endogenous HIF-1a expression. The R167Q and a second Type 2B
mutation (Q195X) have been shown to retain interaction with HIF-
1a [20]. Retention of E3 ligase activity by the remnant R167Q
mutant pVHL-CUL2 VBC complex, therefore, should correspond
to preserved HIF-1a ubiquitylation in vitro.
In vitro-transcribed (TNT) myc-tagged full-length wild type
human HIF-1a (HIF-1a-myc) was subjected to a modified in vitro
ubiquitylation assay, using anti-myc immunoblot to visualize
ubiquitylation of the HIF-1a-myc substrate (Figure 4, components
of each analysis indicated above lane). The HIF-1a-myc protein
migration for each cell line is summarized by a shaded line to the
right of the immunoblot. TNT HIF-1a-myc substrate in the
absence of reaction solution or cell extract served as a negative
control for the unmodified electrophoretic mobility of the HIF-1a-
myc protein. For each cell line in our assay, further controls were
provided by excluding cell extract (first reaction) or TNT HIF-1a-
myc substrate (second reaction). The third reaction for each cell
line contained all three necessary components for the ubiquityla-
tion reaction. An upward shift in HIF1a-myc mobility, as
exemplified by the wild-type (WT) complete reaction, indicates
HIF-1a-myc poly-ubiquitylation. The HIF-1a-myc protein was
shifted only slightly upwards in the reaction utilizing extract from
control vector-only 786-0 cells, demonstrating the basal pVHL-
independent HIF-1a ubiquitylation present in this system. Type
2A Y112H mutant HA-pVHL failed to promote HIF-1a-myc
mobility shift beyond basal levels, confirming previous work by
Cockman et al. [18]. Notably, Type 2B R167Q mutant HA-pVHL
promoted HIF-1a-myc mobility shift similar to WT HA-pVHL,
demonstrating that the remnant R167Q HA-pVHL–Cullin-2
complex retains E3 ligase activity towards HIF-1a in vitro.
Discussion
In addition to the strong association of sporadic ccRCC with
biallelic VHL inactivation and of VHL disease-associated ccRCC
with subtype-specific germline VHL mutations, evidence from
xenograft models of tumor growth strongly supports the
requirement for pVHL-mediated HIF regulation in suppression
of renal tumorigenesis. However, several lines of evidence suggest
that dose-dependent effects on basal HIF levels influence VHL-
associated tumor development and behavior. Our prior investiga-
tion in eupoloid primary ES cell lines, utilized as a strategy to
avoid interference from transforming cancer cell events, demon-
strated a bias toward HIF-2a dysregulation for VHL Type 2B
mutation, and a graduated degree of HIF dysregulation across the
disease subtypes [25]. In vitro studies of RCC-predisposing Type
2A and Type 2B VHL missense mutations have revealed a
correlation between the degree of mutant pVHL-mediated HIF-a
dysregulation and risk of ccRCC [24]. In a recent study performed
in both 786-0 and a second RCC-derived cell line, RCC4,
representative Type 2A and Type 2B VHL mutations demonstrat-
ed intermediate levels of HIF stabilization [21]. Taken together,
these results suggest that Type 2A and Type 2B mutant pVHL
proteins retain an intermediate degree of HIF regulation, rather
than an ‘‘all-or-none’’ pattern of regulation, likely contributing to
the distinct phenotypes observed in these VHL disease subtypes.
In this study, we observed intermediate HIF regulatory activity
by Type 2A Y112H and Type 2B R167Q mutant HA-pVHL,
which could underlie the distinct genotype-phenotype correlations
and may provide insight into the biology of sporadic RCC as well.
In previous reports of VBC complex formation, the ability of
disease-specific mutant pVHL to bind Elongin C was used as a
proxy for ability to recruit the remainder of the VBC complex.
The absence of 2B mutant HA-pVHL interaction with Elongin C
in co-IP studies led to conclusions that a-domain mutations in
pVHL abolish VBC complex formation [13,27–30]. We report
here, however, that both R167Q and D121G Type 2B mutant
HA-pVHL participate in a complex with CUL2, ROC1, and
Elongin B, as well as potentially with Elongin C either transiently
or with greatly reduced abundance.
The co-immunoprecipitation of VBC complex members with
R167Q and D121G mutant HA-pVHL could be due to reduced
Figure 3. Reverse co-immunoprecipitation confirms CUL2-
pVHL protein interaction in R167Q mutation. Anti-myc immuno-
precipitation of myc-CUL2 and associated HA-pVHL in 786-0 clones.
Stable 786-0 clones expressing vector-only (ST) or WT or mutant HA-
pVHL were transiently transfected with wild-type myc-tagged CUL2 and
subjected to myc-IP. Upper panel, IP of Myc-tagged Cul2 detected by
anti-CUL2 immunoblot. Lower panel, co-IP of WT and mutant HA-pVHL
detected by anti-HA immunoblot.
doi:10.1371/journal.pone.0003801.g003
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or transient formation of a wild-type VBC complex and/or
formation of an alternate pVHL-Cullin-2 complex with ubiquitin
ligase activity. The low abundance of Elongins C and B in
association with both representative Type 2B mutant pVHL
proteins may represent a limited quantity of stable complete VBC
complex. Existing crystal structures depict the pVHL a-domain
interacting with the VBC complex only through Elongin C [15].
However, the relatively abundant CUL2 and ROC1 in the mutant
2B VBC complex could point to a direct interaction between
mutant HA-pVHL and CUL2 or the replacement of Elongins C
and B with alternate adaptors linking the mutant HA-pVHL to
CUL2–ROC1. Silver stain and proteomic analysis of our Type 2B
mutant HA-pVHL immunoprecipitates failed to detect additional
bands that could function as replacement adaptors in an alternate
HA-pVHL–CUL2 complex (data not shown).
The Type 2B mutation R167Q has been shown to permit
interaction between pVHL and HIF-a [20]. Therefore, if able to
recruit an active complete or alternate VBC complex, Type 2B
pVHL should be able to direct HIF-a ubiquitylation. Indeed, we
observed that R167Q mutant HA-pVHL existed in complex with
CUL 2 and ROC1 and mediated wild-type levels of HIF-1a poly-
ubiquitylation in vitro. Though the presence of ROC1 has been
shown to stabilize the VBC complex [12], our results cannot
discern whether endogenous levels of Type 2B mutant pVHL
expression support formation of a stable or transient complex with
CUL2. R167Q mutant pVHL has been shown to be relatively
unstable in vitro [24], and subtype-specific clinical manifestations of
VHL disease may derive from a combination of mutant pVHL
stability and the stability and activity of the mutant VBC complex.
In summary, we have demonstrated that disease-associated
mutant pVHL proteins retain endogenous HIF-2a regulation.
Two representative Type 2B mutant pVHL proteins partially
preserved interaction with VBC complex members despite
reduced binding to Elongin C, and the Type 2B mutant R167Q
pVHL retained wild-type levels of ubiquitin ligase activity towards
its target HIF-1a in vitro. Taken together, our results show that at
least a subset of Type 2B VHL missense mutations result in a
partial or unstable but active VBC complex which retains the
ability to regulate HIF-a levels. Furthermore, our results support
observations that VHL missense mutations generally confer lower
levels of HIF-a stabilization than null or truncating Type 1 VHL
mutations [21,25] and provide mechanistic insight into this
retained ubiquitin ligase activity.
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